BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 34610837)

  • 1. Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
    Katayama T; Sawada J; Takahashi K; Yahara O; Hasebe N
    Alzheimers Res Ther; 2021 Oct; 13(1):163. PubMed ID: 34610837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
    J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease.
    Joki H; Higashiyama Y; Nakae Y; Kugimoto C; Doi H; Kimura K; Kishida H; Ueda N; Nakano T; Takahashi T; Koyano S; Takeuchi H; Tanaka F
    J Neurol Sci; 2018 Feb; 385():99-104. PubMed ID: 29406924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex ratio in dementia with Lewy bodies balanced between Alzheimer's disease and Parkinson's disease dementia: a cross-sectional study.
    Mouton A; Blanc F; Gros A; Manera V; Fabre R; Sauleau E; Gomez-Luporsi I; Tifratene K; Friedman L; Thümmler S; Pradier C; Robert PH; David R
    Alzheimers Res Ther; 2018 Sep; 10(1):92. PubMed ID: 30208961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.
    Gmitterová K; Gawinecka J; Llorens F; Varges D; Valkovič P; Zerr I
    Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):461-470. PubMed ID: 30083957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurodegeneration and Glial Activation Related CSF Biomarker as the Diagnosis of Alzheimer's Disease: A Systematic Review and an Updated Meta- analysis.
    Hao Y; Liu X; Zhu R
    Curr Alzheimer Res; 2022; 19(1):32-46. PubMed ID: 34879804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.
    Wang ZY; Han ZM; Liu QF; Tang W; Ye K; Yao YY
    Int Psychogeriatr; 2015 Sep; 27(9):1429-38. PubMed ID: 25851548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies.
    Tam CW; Burton EJ; McKeith IG; Burn DJ; O'Brien JT
    Neurology; 2005 Mar; 64(5):861-5. PubMed ID: 15753423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
    Tateno F; Sakakibara R; Kawai T; Kishi M; Murano T
    Alzheimer Dis Assoc Disord; 2012; 26(3):213-6. PubMed ID: 22037599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.
    Shimada H; Shinotoh H; Hirano S; Miyoshi M; Sato K; Tanaka N; Ota T; Fukushi K; Irie T; Ito H; Higuchi M; Kuwabara S; Suhara T
    Mov Disord; 2013 Feb; 28(2):169-75. PubMed ID: 23225334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of pathological markers in Parkinson's disease dementia post-mortem brains compared to dementia with Lewy bodies.
    Tu H; Zhang ZW; Qiu L; Lin Y; Jiang M; Chia SY; Wei Y; Ng ASL; Reynolds R; Tan EK; Zeng L
    BMC Neurosci; 2022 Jan; 23(1):3. PubMed ID: 34983390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease.
    Mito Y; Yoshida K; Yabe I; Makino K; Hirotani M; Tashiro K; Kikuchi S; Sasaki H
    Clin Neurol Neurosurg; 2005 Aug; 107(5):396-403. PubMed ID: 16023534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
    van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
    J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies.
    Beyer MK; Larsen JP; Aarsland D
    Neurology; 2007 Aug; 69(8):747-54. PubMed ID: 17709706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.